Product Theaters

Product Theaters

Product Theaters offer informative sessions focusing on particular products or a single facet of diabetes. Product Theater sessions do not provide continuing education credit. Breakfast will be served to the first 150 attendees. Lunch will be served at the noon sessions to the first 300 attendees. An afternoon break will be offered to the first 300 attendees at the later sessions. A light dinner will be served to the first 300 attendees in the evening. Several states have enacted state regulations prohibiting sponsoring companies from providing any food, beverages and/or meals to healthcare professionals practicing in those states. Please consult your state regulations and ethics laws to see if such prohibition would apply to you.

In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at this educational program is limited to health care professionals. Accordingly, attendance by guests or spouses is not appropriate and cannot be accommodated.

Ticketing Process

Look for the designated Product Ticket Desk in the registration area. At this counter, attendees can obtain tickets to the various events. Note: Attendees are limited to one (1) ticket per event time. Seats are limited, so get your tickets early.

  • If you change your mind about attending, return the ticket to the Product Ticket Desk.
  • Doors will open 10 minutes before the scheduled start time for attendees with a ticket.
  • Starting 5 minutes after the scheduled start time, organizers reserve the right to allow walk-ins to fill vacant seats. At this time, tickets will be voided.
  • If a ticket was not available at the Product Ticket Desk, check at the door 10 minutes prior to the event to see if space is available.

Thursday Aug.11 5:30 pm – 6:15 pm

PT_novo nordisk color logoPT01 GLP-1 Across the Continuum: From Metformin to Basal Insulin
Ballroom 20A

Supported by Novo Nordisk
This Product theater will describe the changing landscape for managing type 2 diabetes and how GLP-1 and insulin affect the core defects of type 2 diabetes. Explain the multifactorial nature of type 2 diabetes pathophysiology and role of GLP-1 in maintaining normal glucose homeostasis. Explain the shift in managing type 2 diabetes from a traditional to pathophysiologic approach. Outline clinical data related to use of basal insulin as add-on to GLP-1 therapy for the treatment of type 2 diabetes.

Melissa Magwire, RN, CDE, Endocrine Program Coordinator, Shawnee

Friday, Aug. 12 6:30 am – 7:15 am

merck-logo-innovation-innovator-disruption-incubator.gif.pagespeed.ce.aG6-fKNVpTPT02 Helping to Prevent Pneumococcal Disease in Certain Adults
Ballroom 20A

Supported by Merck Co., Inc.
Describe Clinical burden of pneumococcal diseases in adults; define categories of increased risk; and consider strategies to improve processes in your practice.

Laurene Mascola, MD, Chief of the Acute Communicable Disease Control Program, Los Angeles County Department of Public Health

12:15 pm – 1:00 pm

16_AADE_Meeting_Guide_Sponsors_AstraZenecaPT03 The Role of a Once-Weekly GLP-1 RA Therapy in Improving Glucose Control
Exhibit Hall – Product Theater A

Supported by AstraZeneca
This presentation will demonstrate how glucose profiles differ amongst patients with type 2 diabetes and the opportunity to manage glucose fluctuations. The content includes a review of a study that evaluated a specific glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy using Continuous Glucose-Monitoring (GCM) to determine its effect on 24-hour glucose control in patients with type 2 diabetes. Additionally, efficacy of this Once-Weekly GLP-1 RA proven in a series of clinical trials that showed both short and long-term efficacy will also be presented. Concluding the program will be information on the proper device preparation and administration of this Once-Weekly GLP-1 RA therapy.

Robert S. Busch, MD, FACE

12:30 pm – 1:15 pm

PT_Abbott logoPT04 The Value of Retrospective CGM Data in Shared Decision Making
Exhibit Hall – Product Theater B

Supported by Abbott Diabetes Care
In this Product Theater, you will learn how the Ambulatory Glucose Profile (AGP) and CGM data can facilitate shared decision-making helping you advance a new standard of personalized diabetes care.

Davida Kruger, MSN, APN-BC, CNP, Certified Nurse Practitioner – Diabetes, Henry Ford Health System
Virginia Valentine, APRN-CNS, BC-ADM, CDE, FAADE, Clinical Nurse Specialist, Northside Family Medicine

Saturday, Aug. 13 6:30 am – 7:15 am

PT_BI_Lilly logoPT05 Options in Basal Insulin: Basaglar® (Insulin Glargine Injection)
Exhibit Hall – Product Theater A

Supported by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC
This program will discuss an FDA-approved insulin glargine option from the Boehringer Ingelheim and Eli Lilly and Company Alliance. The presentation will provide information regarding the BASAGLAR clinical profile, as well as dosing and administration. Attendees will have the opportunity to ask the faculty questions about the data presented and refreshments will be provided.

Eugene E. Wright, Jr., MD, Consulting Associate, Department of Medicine and Community and Family Medicine Duke University School of Medicine

11:45 am – 12:30 pm

PT_Janssen_Hor_u_CMYKPT06 Going Further in the Treatment of Adults with T2DM: A Leading Option After Metformin
Exhibit Hall – Product Theater A

Supported by Janssen Pharmaceuticals, Inc.
This program will cover the following topics regarding a sodium-glucose co-transporter (SGLT2) inhibitor: the role of the kidney in regulation of hyperglycemia in T2DM, the mechanism of action- mediated inhibition of SGLT2 in the proximal convoluted tubule of the kidney, key efficacy and safety data from active-controlled clinical trials, Important Safety Information, questions and answer session. This promotional educational activity is sponsored by Janssen Pharmaceuticals, Inc. It is not certified for continuing medication education.

Debbie Hinnen, RN, ARNP, BC-ADM, CDE, FAAN, FAADE, Advanced Practice Nurse, Memorial Hospital, University of Colorado
Virginia Valentine, APRN-CNS, BC-ADM, CDE, FAADE, Clinical Nurse Specialist, Northside Family Medicine
Davida Kruger, MSN, APN-BC, CNP, Certified Nurse Practitioner – Diabetes, Henry Ford Health System

12:00 pm – 12:45 pm

PT_AscensiaPT07 The Impact of Blood Glucose Monitoring System Accuracy on Diabetes Management
Exhibit Hall – Product Theater B

Supported by Ascensia Diabetes Care
This product theater presentation will discuss the importance of BGMS accuracy, review current accuracy standards, and provide information on the CONTOUR NEXT portfolio of BGMS.

Gary Scheiner, MS, CDE, Owner and Clinical Director, Integrated Diabetes Services

2:45 pm – 3:30 pm

RochePT08 Integrating Diabetes Technology into Daily Life
Exhibit Hall – Product Theater A

Supported by Roche Diabetes Care, Inc.
Diabetes technology is only as valuable as a patient’s ability to easily use it every day. Receiving meaningful and actionable data empowers both patients and their care team to make more-informed decisions. Join us to learn how new technology like the Accu-Chek Connect system provides care teams with solutions that can help improve outcomes, while gaining efficiencies in the office. We will also unveil our new Accu-Chek Assist website, designed to save you time. It identifies the patient’s most affordable option for Accu-Chek test strips and gives them a user-friendly guide for setting up and using their new meter.

Anne Peters, MD, CDE, Professor, Keck School of Medicine of USC

2:45 pm – 3:30 pm

PT_SANOFI_Logo_vertical 2011_4colorsPT09 Toujeo® (Insulin Glargine Injection) 300 Units/mL — A Once Daily Basal Insulin: Clinical Overview and Features
Exhibit Hall – Product Theater B

Supported by Sanofi
Toujeo® (insulin glargine injection) 300 Unit/mL is a long-acting basal insulin indicated to improve glycemic control in adult patients with diabetes mellitus. This presentation is intended to provide clinicians with a comprehensive overview of Toujeo®, including the pharmacologic profile and data from 4 EDITION clinical trials carried out in a range of adult patients with diabetes. Please see full prescribing information for Toujeo® at the Sanofi booth 1226.

Melissa Magwire RN, CDE, Endocrine Program Coordinator, Shawnee Mission Endocrinology and Diabetes

Sunday, Aug. 14 6:30 am – 7:15 am

MedtronicPT10 MiniMed® System with SmartGuard™ Technology: Driving Patient Outcomes Through Automation
Exhibit Hall – Product Theater A

Supported by Medtronic
1 out of 2 patients with diabetes will experience nocturnal hypoglycemia at least once per night. 7 out 10 alter their insulin due to fear of hypoglycemia. Come find out how the MiniMed® system with SmartGuard™ technology takes action against lows and can help you drive better outcomes for your patients.

Fran Kaufman, MD, Pediatric Endocrinologist, Chief Medical Officer & Vice President, Global Medical, Clinical and Health Affairs

12:15 pm – 1:00 pm

PT_regeneron_logo_blue_RGBPT11 Eye Health and the Diabetic Patient
Exhibit Hall – Product Theater A

Supported by Regeneron Pharmaceuticals, Inc.
The goal of the Product Theater is to provide an overview of eye health, risks of diabetes on eye health, types of eye examinations, diabetic macular edema, treatment options and answer questions from attendees.

Atul Jain, MD, San Diego Retina Associates

12:30 pm – 1:15 pm

PT_SANOFI_Logo_vertical 2011_4colorsPT12 The Importance of Utilizing a Comprehensive Approach when Managing Patients with T2DM
Exhibit Hall – Product Theater B

Supported by Sanofi
T2DM is a complex, progressive disease. As the number of patients with diabetes increases, it is critical to take a closer look at the ongoing challenges of getting patients to glycemic goal despite the availability of medications and detailed treatment guidelines. In this presentation, we will take a closer look at the effects of hyperglycemia prior to diabetes diagnosis, the importance of achieving individualized glycemic goals, the current diabetes treatment landscape, and finally, the potential of multifactorial approaches to treatment.

Jonathan G. Marquess, PharmD, CDE, FAPhA, President, The Institute for Wellness and Education, Inc., A Disease Management Company

Social media & sharing icons powered by UltimatelySocial